Latest News and Press Releases
Want to stay updated on the latest news?
-
Schindellegi, Switzerland – 20 April 2026 Trifork Group AGCompany announcement no. 26/2026 Share-based incentive program 2026 Trifork Group AG (“Trifork”) has granted restricted share units...
-
Íþaka fasteignir ehf., kt. 450613-2580, Lynghálsi 4, 110 Reykjavík, útgefandi í skuldabréfaflokkum ITHAKA 070627, ITHAKA 291128, ITHAKA 051233 og ITHAKA 300834, boðar til kynningarfundar fyrir...
-
Intern viden ALLIANCE fase 2‑studiet demonstrerede proof‑of‑concept efter kun 6 måneders vedligeholdelsesbehandling i en bred patientgruppe bestående af både børn og voksne.Klar dosisafhængig og...
-
Inside Information The ALLIANCE phase 2 trial demonstrated proof-of-concept after only 6 months of maintenance treatment in a broad patient population comprising both children and adults.Clear...
-
Til Nasdaq Copenhagen A/S DirektionenBernstorffsgade 401577 København Vwww.rd.dkTelefon 7012 530020. april 2026 Selskabsmeddelelse nummer 32/2026 Ekstraordinære indfrielser, Realkredit Danmark A/S I...
-
To Nasdaq Copenhagen A/S Executive ManagementBernstorffsgade 40DK-1577 København Vwww.rd.dkTelephone +45 7012 530020 April 2026 Company Announcement No 32/2026 Prepayments, Realkredit Danmark A/S ...
-
Med henvisning til meddelelse af 9. marts 2026 om, at Lise Bøgelund Jensen har opsagt sin stilling som administrerende direktør i foreningens administrationsselskab, Wealth Fund Partners A/S, har...
-
Equinor ASAs (OSE: EQNR, NYSE: EQNR) ordinære generalforsamling finner sted tirsdag 12. mai 2026 klokken 15.00 CEST. Generalforsamlingen vil bli avholdt i Equinor Business Center, Forusbeen 50, 4035...
-
The annual general meeting of Equinor ASA (OSE: EQNR, NYSE: EQNR) will be held Tuesday 12 May 2026 at 15:00 CEST. The annual general meeting will be held in Equinor Business Center, Forusbeen 50,...
-
Etavopivat showed a 27% reduction in vaso-occlusive crisis events and ~4-month delay to first vaso-occlusive crisis event on top of standard of care1Haemoglobin response was superior with...